---
title: "12 Health Care Stocks Moving In Friday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298063391.md"
description: "In Friday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Immuron (up 48.2%), bioAffinity Technologies (up 39.12%), and Veraxa Biotech Holding (up 18.62%). Conversely, Losers featured BioXcel Therapeutics (down 27.1%), Clearmind Medicine (down 17.65%), and Bristol-Myers Squibb Celegne Contingent Value Rights (down 17.25%). The article highlights specific price movements and market caps for these companies."
datetime: "2026-09-04T17:06:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298063391.md)
  - [en](https://longbridge.com/en/news/298063391.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298063391.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's Intraday Session

### Gainers

-   **Immuron** (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million.
-   **bioAffinity Technologies** (NASDAQ:BIAF) shares rose 39.12% to $17.78. The company's market cap stands at $7.5 million.
-   **Veraxa Biotech Holding** (NASDAQ:VRXA) stock rose 18.62% to $1.81. The market value of their outstanding shares is at $216.3 million.
-   **Pro-Dex** (NASDAQ:PDEX) shares rose 17.26% to $72.41. The market value of their outstanding shares is at $197.3 million. As per the news, the Q4 earnings report came out yesterday.
-   **GRI Bio** (NASDAQ:GRI) shares moved upwards by 16.78% to $2.67. The company's market cap stands at $5.0 million.
-   **NeuroSense Therapeutics** (NASDAQ:NRSN) stock moved upwards by 16.13% to $0.47. The market value of their outstanding shares is at $14.4 million.

### Losers

-   **BioXcel Therapeutics** (NASDAQ:BTAI) stock declined by 27.1% to $0.09 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
-   **Clearmind Medicine** (NASDAQ:CMND) stock decreased by 17.65% to $1.4. The market value of their outstanding shares is at $2.5 million.
-   **Bristol-Myers Squibb Company Celegne Contingent Value Rights** (NYSE:CELGR) shares fell 17.25% to $0.12.
-   **Cyclerion Therapeutics** (NASDAQ:CYCN) shares decreased by 14.92% to $4.22. The company's market cap stands at $23.2 million.
-   **Jaguar Health** (NASDAQ:JAGX) stock decreased by 12.81% to $0.61. The market value of their outstanding shares is at $3.5 million.
-   **ZeroStack** (NASDAQ:ZSTK) stock decreased by 9.96% to $4.34. The company's market cap stands at $11.6 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [IMRN.US](https://longbridge.com/en/quote/IMRN.US.md)
- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)
- [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md)
- [BTAI.US](https://longbridge.com/en/quote/BTAI.US.md)
- [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)
- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [IMC.AU](https://longbridge.com/en/quote/IMC.AU.md)
- [BTAIQ.US](https://longbridge.com/en/quote/BTAIQ.US.md)
- [PDEX.US](https://longbridge.com/en/quote/PDEX.US.md)
- [GRI.US](https://longbridge.com/en/quote/GRI.US.md)
- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [CYCN.US](https://longbridge.com/en/quote/CYCN.US.md)
- [JAGX.US](https://longbridge.com/en/quote/JAGX.US.md)
- [ZSTK.US](https://longbridge.com/en/quote/ZSTK.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial](https://longbridge.com/en/news/298308696.md)
- [Clearmind enrolls first AUD patients in CMND-100 clinical trial](https://longbridge.com/en/news/298727898.md)
- [Clearmind Medicine Inc. GAAP EPS of -$0.57](https://longbridge.com/en/news/298641285.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**